BDH Industries Ltd
Incorporated in 1935, BDH Industries Ltd manufactures therapeutic formulations covering wide range of pharmaceuticals[1]
- Market Cap ₹ 201 Cr.
- Current Price ₹ 350
- High / Low ₹ 418 / 175
- Stock P/E 20.7
- Book Value ₹ 110
- Dividend Yield 1.29 %
- ROCE 20.6 %
- ROE 16.9 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 27.7%
Cons
- The company has delivered a poor sales growth of 10.7% over past five years.
- Debtor days have increased from 92.8 to 121 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
40.16 | 42.38 | 44.27 | 45.84 | 43.18 | 40.94 | 51.69 | 59.48 | 57.45 | 69.39 | 74.46 | 85.83 | 80.66 | |
36.86 | 38.71 | 40.47 | 41.77 | 38.37 | 35.58 | 44.69 | 50.51 | 48.94 | 60.30 | 63.50 | 73.40 | 68.35 | |
Operating Profit | 3.30 | 3.67 | 3.80 | 4.07 | 4.81 | 5.36 | 7.00 | 8.97 | 8.51 | 9.09 | 10.96 | 12.43 | 12.31 |
OPM % | 8.22% | 8.66% | 8.58% | 8.88% | 11.14% | 13.09% | 13.54% | 15.08% | 14.81% | 13.10% | 14.72% | 14.48% | 15.26% |
0.74 | 1.23 | 1.22 | 1.80 | 1.24 | 0.82 | 0.89 | 0.80 | 1.30 | 1.33 | 0.84 | 1.58 | 1.61 | |
Interest | 0.83 | 0.74 | 0.48 | 0.33 | 0.35 | 0.25 | 0.52 | 0.69 | 0.28 | 0.23 | 0.16 | 0.18 | 0.18 |
Depreciation | 0.72 | 0.76 | 0.74 | 0.73 | 0.72 | 0.75 | 0.83 | 0.96 | 0.79 | 0.63 | 0.57 | 0.57 | 0.76 |
Profit before tax | 2.49 | 3.40 | 3.80 | 4.81 | 4.98 | 5.18 | 6.54 | 8.12 | 8.74 | 9.56 | 11.07 | 13.26 | 12.98 |
Tax % | 32.53% | 32.65% | 32.11% | 33.06% | 33.13% | 27.22% | 26.30% | 26.72% | 27.35% | 24.37% | 25.84% | 25.49% | |
1.67 | 2.30 | 2.57 | 3.23 | 3.34 | 3.76 | 4.83 | 5.94 | 6.36 | 7.22 | 8.20 | 9.87 | 9.72 | |
EPS in Rs | 2.90 | 3.99 | 4.46 | 5.61 | 5.80 | 6.53 | 8.39 | 10.32 | 11.05 | 12.54 | 14.24 | 17.14 | 16.89 |
Dividend Payout % | 35.57% | 30.99% | 39.29% | 36.78% | 35.57% | 35.55% | 33.82% | 25.00% | 28.02% | 28.72% | 28.10% | 26.26% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 11% |
3 Years: | 14% |
TTM: | 11% |
Compounded Profit Growth | |
---|---|
10 Years: | 16% |
5 Years: | 15% |
3 Years: | 16% |
TTM: | 23% |
Stock Price CAGR | |
---|---|
10 Years: | 24% |
5 Years: | 41% |
3 Years: | 38% |
1 Year: | 83% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 16% |
3 Years: | 16% |
Last Year: | 17% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.94 | 5.94 | 5.94 | 5.94 | 5.94 | 5.94 | 5.94 | 5.94 | 5.94 | 5.76 | 5.76 | 5.76 | 5.76 |
Reserves | 15.91 | 17.18 | 18.14 | 21.36 | 23.29 | 25.32 | 28.40 | 32.30 | 37.13 | 42.83 | 48.94 | 56.40 | 57.79 |
7.76 | 11.33 | 8.88 | 9.47 | 8.43 | 7.53 | 12.99 | 9.22 | 8.51 | 2.25 | 4.85 | 8.69 | 3.70 | |
12.08 | 13.75 | 18.61 | 15.28 | 16.72 | 18.10 | 18.42 | 17.68 | 19.31 | 18.07 | 20.48 | 22.57 | 20.83 | |
Total Liabilities | 41.69 | 48.20 | 51.57 | 52.05 | 54.38 | 56.89 | 65.75 | 65.14 | 70.89 | 68.91 | 80.03 | 93.42 | 88.08 |
15.07 | 14.69 | 13.22 | 13.10 | 22.94 | 22.59 | 22.02 | 21.10 | 20.31 | 19.61 | 19.03 | 20.35 | 19.94 | |
CWIP | 0.00 | 0.06 | 0.00 | 4.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 | 0.35 | 0.35 |
26.62 | 33.45 | 38.35 | 34.90 | 31.44 | 34.30 | 43.73 | 44.04 | 50.58 | 49.30 | 60.65 | 72.72 | 67.79 | |
Total Assets | 41.69 | 48.20 | 51.57 | 52.05 | 54.38 | 56.89 | 65.75 | 65.14 | 70.89 | 68.91 | 80.03 | 93.42 | 88.08 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
5.00 | 3.87 | 6.19 | 4.31 | 7.21 | -0.15 | -3.62 | 11.35 | 0.78 | 3.02 | 6.29 | -1.87 | |
-0.54 | -0.45 | -0.14 | -4.66 | -5.28 | 0.40 | 0.59 | 0.74 | 1.29 | 1.38 | 0.49 | -0.31 | |
1.31 | 2.89 | -3.26 | -0.59 | -2.77 | -2.54 | 3.39 | -6.37 | -2.44 | -8.21 | 0.37 | 1.36 | |
Net Cash Flow | 5.77 | 6.31 | 2.79 | -0.94 | -0.83 | -2.29 | 0.36 | 5.72 | -0.37 | -3.81 | 7.15 | -0.82 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 79.89 | 68.04 | 80.88 | 63.78 | 67.37 | 63.48 | 88.97 | 67.62 | 96.44 | 76.38 | 81.57 | 120.60 |
Inventory Days | 50.41 | 65.19 | 70.93 | 61.18 | 39.41 | 95.20 | 88.97 | 50.59 | 53.31 | 50.00 | 52.59 | 30.28 |
Days Payable | 123.84 | 143.99 | 201.25 | 162.04 | 191.94 | 244.14 | 188.21 | 157.61 | 171.21 | 122.59 | 138.98 | 127.90 |
Cash Conversion Cycle | 6.46 | -10.76 | -49.44 | -37.08 | -85.16 | -85.47 | -10.27 | -39.40 | -21.46 | 3.79 | -4.81 | 22.98 |
Working Capital Days | 35.08 | 23.43 | -2.47 | 3.74 | -26.37 | 4.90 | 62.56 | 25.22 | 60.23 | 68.07 | 72.35 | 108.27 |
ROCE % | 11.82% | 12.96% | 12.67% | 14.69% | 14.32% | 14.21% | 16.40% | 18.59% | 18.21% | 18.24% | 20.35% | 20.61% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Nov - Standalone Unaudited Financial Results for the second quarter and half year ended on 30th September 2024 of the financial year 2024-25 published in newspapers.
- Standalone Unaudited Financial Results For The Second Quarter And Half Year Ended 30Th September 2024 Of The Financial Year 2024-25. 12 Nov
-
Board Meeting Outcome for Outcome Of Board Meeting
12 Nov - Approval of standalone unaudited financial results for Q2 2024-25.
-
Board Meeting Intimation for Considering And Approving The Standalone Unaudited Financial Results For The Second Quarter And Half Year Ended On 30Th September 2024 Of The Financial Year 2024-25.
4 Nov - Board meeting to consider Q2 financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
18 Oct - Certificate under Regulation 74(5) of SEBI (Depositories and Participants ) Regulations 2018 for the quarter ended 30th September 2024 is enclosed herewith for reference.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
BDHIL is a full-service Contract Manufacturing Organization for production of Pharmaceutical, Oncological Products and associated packaging services. It is an exporter and manufacturer of therapeutic formulations covering a wide range of pharmaceuticals